Healthcare / Medical DevicesTSXV
$0.01
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-32810.00 · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$439380
P/E
N/A
•EV/EBITDA
N/A
•ROE
-80.3%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
-1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $31240.0 · FCF $-32810.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $31240.00 | $31240.00 | $-114767.00 | $-90525.00 | $1.2M |
| EBITDA | $-115760.00 | $-115760.00 | $-114767.00 | $-136269.00 | $-287990.00 |
| EPS | — | — | — | — | 0.07 |
| Balance Sheet | |||||
| Current Ratio | 0.11 | 0.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-32810.00 | $-32810.00 | $-27962.00 | $-110731.00 | $-180574.00 |
| Returns | |||||
| ROE | -80.3% | -80.3% | 163.6% | 796.0% | -24841.6% |
| Valuation | |||||
| P/E | — | — | — | — | 0.21 |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.